Immunovant (IMVT) Prices 5.27M Share Common Stock Offering at $33/Each

Immunovant, Inc. (Nasdaq: IMVT) today announced the pricing of its underwritten public offering of 5,270,093 shares of its common stock at a price to the public of $33.00 per share. The aggregate gross proceeds to Immunovant from the offering are expected to be approximately $173.9 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Immunovant. The offering is expected to close on September 4, 2020, subject to customary closing conditions. In connection with this offering, Immunovant has granted the underwriters a 30-day option to purchase up to an aggregate of 790,513 additional shares of common stock on the same terms and conditions. If the underwriters exercise this option in full, the aggregate gross proceeds to Immunovant from the offering would be approximately $200.0 million, before deducting underwriting discounts and commissions and offering expenses.

SVB Leerink, Guggenheim Securities and Chardan are acting as joint bookrunning managers for the offering. LifeSci Capital LLC and Baird are acting as the co-lead managers for the offering.

You May Also Be Interested In

• Zentalis Pharmaceuticals prices $80.5M public stock offering
• Zentalis Pharmaceuticals launches public stock offering
• Baird Downgrades Accendra Health Inc. (ACH) to Neutral